Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Income from Continuing Operations (2020 - 2025)

Insight Molecular Diagnostics' Income from Continuing Operations history spans 6 years, with the latest figure at 11048000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 18.25% year-over-year to 11048000.0; the TTM value through Sep 2025 reached 61316000.0, down 41.1%, while the annual FY2024 figure was 61041000.0, 142.84% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 11048000.0 at Insight Molecular Diagnostics, down from 9842000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 9312000.0 in Q4 2022 and bottomed at 35691000.0 in Q4 2021.
  • The 5-year median for Income from Continuing Operations is 8333000.0 (2023), against an average of 9754947.37.
  • The largest annual shift saw Income from Continuing Operations crashed 438.57% in 2021 before it surged 274.6% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 35691000.0 in 2021, then skyrocketed by 126.09% to 9312000.0 in 2022, then tumbled by 273.74% to 16179000.0 in 2023, then crashed by 107.84% to 33627000.0 in 2024, then surged by 67.15% to 11048000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Income from Continuing Operations are 11048000.0 (Q3 2025), 9842000.0 (Q2 2025), and 6799000.0 (Q1 2025).